Brainstorm Cell Therapeutics Inc. (BCLI)

BCLI Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	1.3	0.77	18.86	37.83	0.54
Short-Term Investments	0	2.21	3.24	4.11	0.03
Cash & Cash Equivalents	1.3	2.98	22.09	41.94	0.57
Cash Growth	-56.42%	-86.50%	-47.31%	7270.12%	-91.95%
Receivables	0.05	0.09	0.09	0.3	2.36
Other Current Assets	0.55	0.03	1.1	1	0.43
Total Current Assets	1.9	3.11	23.28	43.24	3.36
Property, Plant & Equipment	2.1	5.32	5.97	7.99	3.14
Long-Term Investments	0.19	0	0	0	0
Other Long-Term Assets	0.02	0.02	0.03	0.03	0.03
Total Long-Term Assets	2.31	5.35	6	8.02	3.17
Total Assets	4.21	8.45	29.28	51.26	6.53
Accounts Payable	4.95	6.22	4.77	7.32	15.39
Current Debt	0.6	1.43	1.46	2.66	1.26
Other Current Liabilities	2.24	1.15	0.08	1.26	1
Total Current Liabilities	7.8	8.8	6.32	11.23	17.65
Long-Term Debt	0.67	2.67	3.62	4.56	1.1
Other Long-Term Liabilities	0.59	0	0	0	0
Total Long-Term Liabilities	1.27	2.67	3.62	4.56	1.1
Total Liabilities	9.07	11.47	9.94	15.8	18.76
Total Debt	1.28	4.09	5.08	7.22	2.37
Debt Growth	-68.85%	-19.41%	-29.62%	205.03%	-
Retained Earnings	-215.01	-197.82	-173.54	-149.09	-117.28
Shareholders' Equity	-4.86	-3.02	19.34	35.46	-12.22
Net Cash / Debt	0.03	-1.11	17.02	34.72	-1.8
Net Cash / Debt Growth	-	-	-50.99%	-	-
Net Cash Per Share	0.00	-0.03	0.47	1.16	-0.08
Working Capital	-5.9	-5.69	16.96	32.01	-14.29
Book Value Per Share	-0.11	-0.08	0.54	1.19	-0.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).